William Creasman to Tamoxifen
This is a "connection" page, showing publications William Creasman has written about Tamoxifen.
Connection Strength
0.550
-
What is the significance of gynecologic symptoms in the participants in the NSABP study? Am J Obstet Gynecol. 2011 Dec; 205(6):511-2.
Score: 0.376
-
Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991 Jul 15; 68(2):269-71.
Score: 0.093
-
Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol. 1997 Feb; 24(1 Suppl 1):S1-140-S1-50.
Score: 0.034
-
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol. 1996 Jul; 62(1):4-6.
Score: 0.033
-
Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1984 May; 68(5):809-11.
Score: 0.014